The effect of disease modifying therapies on CD62L expression in multiple sclerosis

Multiple Sclerosis Journal – Experimental, Translational and Clinical

Margarete MariaVoortman¹ 

关键词: CD62L;    lymphocytes;    multiple sclerosis;    clinically isolated syndrome;    disease-modifying therapies;    immunology;   

DOI  :  10.1177/2055217318800810

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

BackgroundThe increasing armamentarium of disease-modifying therapies in multiple sclerosis is accompanied by potentially severe adverse effects. The cell-adhesion molecule CD62L, which facilitates leukocyte extravasation, has been proposed as a predictive marker for treatment tolerability. However, pre-analytical procedures might impact test results, thereby limiting its clinical usability. Whether the immediate analysis of CD62L expression of peripheral blood mononuclear cells can aid treatment decision making is yet unclear.ObjectiveTo investigate the effect of various disease-modifying therapies in multiple sclerosis on CD62L expression of CD3+CD4+ peripheral blood mononuclear cells in freshly collected blood samples.MethodsWe collected peripheral blood samples from patients with clinically isolated syndrome and multiple sclerosis (baseline/follow up n = 234/n = 98) and healthy controls (n = 51). CD62L+CD3+CD4+ expression was analysed within 1 hour by fluorescence-activated cell sorting.ResultsCD62L+C...

【 授权许可】

CC BY-NC